Blog Page 987

TECHNOLOGY: Physician email and IT use

0

This is one of those, "I’m glad they wrote it so I didn’t have to," posts. iHealthbeat has two articles updating physician use of email and physician IT use. You may have seen smatterings of some of the studies used there before in in this blog, but these are two excellent summary articles. Caroline Broder has an expanded summary about the state of play in her column about online consultations , and the ever-wonderful Jane Sarasohn Kahn puts some recent surveys of IT in the doctor’s office into perspective.  Both wonderful reads, so go read them.

Meanwhile, my long promised piece on PDA and physician EMR use is still in the production queue….

UPDATE: CHCF also has a new report out from First Consulting Group on how providers should select and introduce patient-physician email communication systems.

PHARMA: New free-market ideas on counter-detailing

0

Arnold Relman, former editor of the NEJM and long term opponent of for-profit health care, has an op-ed piece in the NY Times complaining about the  impact of pharma companies sponsoring CME. Relman suggests getting pharma companies out of CME.  This is an old chestnut from Relman and I wouldn’t usually link to this other than to note that while the pharmas throw alot of mud at the CME wall, they’re not too sure whether it’ll stick–and it’s done as much as part of a competitive arms race than based on  too much pure marketing science.

But Donald Johnson, who’s really getting into his stride after a few quiet weeks at The Business Word has a more interesting, free-market suggestion: Have the payers pay doctors to attend counter-detailing CME sessions!

POLICY: Just in case you thought the AARP endorsement sealed it…

0

The AARP’s endorsement is supposed to have sealed the Medicare Bill–but just take a look at this message board which spews vitriol towards AARP from its own members! Hundreds of messages here are all opposed to the Bill. I picked this one at random:

    Who can we turn to for help when AARP stabs us in the back?  How can you support a proposal that enriches only private insurance and pharmaceutical companies, leaving seniors with a broken Medicare program?  Shame on you.

Meanwhile, despite a down day on the stock market the drug stocks and the PBM stocks held steady, consolidating their gains of last week.  So Wall Street is convinced that the bill will get by.  To be fair, the "non-controversial" part of the bill–the new drug benefit–is fabulously loaded towards pharma companies and PBMs, for now.  And as a separate package that would pass on its own.

PHARMA/PBMs: Are Cox-2 inhibitors over-used?

0

Cox-2 Inhibitors have been a major therapeutic class since their introduction in the late 1990s. Led by Pfizer’s Celebrex and Merck’s Vioxx, the pain-relievers are roughly a $6bn market–not as large as the statin market but nothing to sneeze at.  These drugs have been aimed primarily at arthritis’ sufferers, in particular at the substantial minority who have had stomach problems from regimes using traditional painkillers like ibuprofen or NSAIDs. But in recent years the growth of the market has slowed due to several setbacks, including a 2001 JAMA report of cardiovascular side-effects, and suggestions that COX-2 inhibitors might impede blood vessel creation  (for wound repair), and also suggestions that Celebrex wasn’t as good for gastro-irritation as was promised. Additionally two new Cox-2 inhibitors have had their approval delayed. These are Prexige from Novartis that won’t appear in the US until 2005 although it is already approved in the UK, and Arcoxia, Merck’s new COX-2 inhibitor.

But looked at another way, COX-2 inhibitors have been an example of big pharma’s ability to change patient and physician behavior. Don’t forget that this class of drugs doesn’t offer any superior pain relief than ibuprofen or NSAIDs, and costs seven to ten times as much.  The reason for their success is that they reduce associated stomach irritation. Of course that means that people who don’t have that kind of irritation from long-term ibuprofen use shouldn’t need to go on COX-2 inhibitors, at least until they have some other symptom or reach a certain age (often 60 is used).  So the PBMs, health plans and other formulary enforcers have a tricky job.  They have to battle the weight of the pharma DTC advertising and physician promotion in order to get patients to stay with the OTC or generics.

Well it appears that they are not succeeding. A new report in The American Journal of Managed Care from PBM, Express Scripts, looked at new users of COX-2 in 2000 at a PPO. 65% had no indication of being at risk for gastrointestinal events. Furthermore 68% had not tried an NSAID first.  In the study only 18% of the population were over 60–one of the minimum required indicators for going straight to COX-2.  In other words,  in order to be somewhat conservative about costs in a sub-Medicare populations almost everyone should be first trying NSAIDs or ibuprofen. In fact over 60% are going straight to COX-2 inhibitors.

You can look at this two ways. Perhaps there should be a 60% reduction in COX-2 use.  Or perhaps PBMs and formularies are ineffective in the face of the pharmas.  Either way what’s happening now is presumably not the right answer. Given that there’ll be new COX-2 drugs on the market soon and PBMs are going to be used by Medicare (Maybe!) to restrict Medicare drug costs, the question of how this gets resolved is key for the future of PBMs’ credibility.

HEALTH PLANS: Kaiser CEO interview

0

The Sunday San Francisco Chronicle had a somewhat rambling interview with Kaiser CEO George Halvorson. The main isues he raised were:
a) the conversion from an acute to a chronic health system raises costs
b) Kaiser is committed to evidence-based practice improvement–and will spend $3bn on the EMR that is supposed to get it there–and that IT might reduce costs enventually.
c) Halvorson wants universal coverage but not single payer (but has no real idea how to get there unless Brazil is the model!).
d) Hospital consolidation has meant that Kaiser has had to continue building its own facilities. (My comment: because they can’t buy cheaply on the margin like they could in the mid-1990s).
e) As an HMO-only model they are in trouble from competition from high deductible plans, and institutionally a closed system like Kaiser cannot create these products.

His last comments are certainly true. For an example I plugged myself into the PacAdvantage system. (PacAdvantage is a small business buying coalition formerly known as CalHIPC).  The Healthnet PPO saver with a $500 deductible and $2,500 max out of pocket is $72 a month.  The Kaiser plan is the cheapest of the HMOs but it costs $137 for the same yearly maximum out of pocket–although it has no deductible. So the premium difference is $800 a year!  Consequently Kaiser has been losing members to the high deductible lower premium plans, as employers push their employees towards them.  Internally Kaiser had planned for growth in 2003, but instead it’s losing members overall.

POLICY: Medicare agreement-is it a charade?

0

So while the news says that the bill is out of conference on Friday and has enough backing to get through, Ted Kennedy basically said  on Sunday that the Medicare bill wasn’t going to make it past him in the Senate. Frist and Hastert meanwhile are trying to broker a bill, without upsetting their conservative wing who (correctly) believe that this bill is a recipe for more cost-unconscious spending in Medicare.  On the other hand as explained at length already here and here, the liberal Democrats and some liberal Republicans like Olympia Snowe are opposed to (or at the least very wary of) the introduction of cost controls or competition/premium support. Jeanne Scott has written a full newsletter this weekend about Medicare (and if you haven’t subscribed yet….). What does she make of all this?

    Just Between You Me. Never ever step on Bill Thomas’ toes!  The sometimes curmudgeonly, but always very powerful, Ways and Means Chair, is reported to believe that the proposal does not do enough to make Medicare fiscally sustainable. And he definitely was not happy that a deal had been cut over his head. Walking with his feet, Thomas left the conference room, threatening to fly home to California rather than accept the imposed deal. Later he was reported meeting with House Energy and Commerce Committee Chaircritter W.J. "Billy" Tauzin (R-La.), hoping to draw up an alternative to the Frist and Hastert’s proposal. The Republican criticism raises the possibility that, if Mr. Frist can’t hold his own party together for the deal, that it won’t survive a yes-or-no vote in the Senate, let alone a filibuster situation demanding 60 votes to cut off debate. Don’t hold your breath on passage by this coming Friday.

    So Where are We After All of This? Conservatives say the cost containment and market components of the bill do not go far enough to hold down spending as baby boomers strain the program’s spending. Liberals say the reforms threaten the very existence of Medicare and constitute the first step toward privatizing one of the most popular government social programs. Don’t hold your breath, but there may be life in the old gal yet.

My sense is that Medicare remains unreformable given the parity in the Congress and the huge political gulf between the Conservative House Republicans and the old style Liberals in the Senate.  But given that the election next year is going to be about Iraq and the economy, I’m not sure that Bush is willing to over-ride his fiscal conservative allies on the fiscal issue in order to get a bill through at any cost. Meanwhile, the bill’s lack of popularity with many seniors is probably enough to sustain a filibuster, so that Ted Kennedy can claim that he saved Medicare.

My guess is that nothing gets by this week. And thus I’m now officially short one of the PBM stocks (in a tiny and cautious way!).

Update The Business Word has another take on this, and I’m glad to say that Donald Johnson over there has been blogging much more regularly of late.  But he too believes that the bill may not happen.  I’m sure we both agree that it’s disapointing that what is a necessary reform for Medicare (adding drug coverage) has been so politicized.  However, AARP’s endorsement may not be such a great thing, especially given the questionable popularity of the bill amongst middle income seniors.  Here’s Jeanne Scott on AARP’s last intervention in Medicare drug coverage:

    And AARP May Screw Seniors Yet Again: AARP (formerly the American Association of Retired Persons, now just plain old “AARP”) may put the screws to seniors again, just like it did in 1988 when it killed the first Medicare Rx proposal. In 1988, AARP orchestrated a highly misleading campaign to convince seniors that they were being unfairly taxed to support the new Rx program  — that law called for a 10% “surtax” to be paid on the federal taxes owed by seniors. Every grandmother in the country was told she would have to pay a “tax” when in fact fewer than 12% of all seniors would have paid any tax (10% of “0” is still “0”), and only a handful would have paid more than they might have received back. AARP did this then because it wanted to save its highly profitable “Medi-Gap” insurance business and could care less about its senior members. AARP now may give the “new and improved” Medicare its seal of approval and in return get guarantees that its for-profit subsidiary operations will have an opportunity to participate.  The AARP orchestrated phony “senior sticker shock” of 1988 may be conspicuously absent when seniors face a real sticker shock in 2006.

PHARMA: Stock update and Medicare

0

While the PBM stocks have been going up, the same thing is happening to the big pharma stocks, as you can see in this chart of a pharma stock index , and in the performance of Merck’s near 10% surge in the last 3 days. There’s more in this Forbes article.

However, the legislation may have been sent out from the conference committee, but it has three major pieces undecided. These include the issues of competition, long-term cost control and Health Savings Accounts.  If they couldn’t get a solution out of the two moderate Democrats on the committee, is there really a chance that this will get past Ted Kennedy? Lefty economist Paul Krugman explains why not.

So I’m still pondering shorting the PBMs…..

POLICY: More on uninsurance

0

A while back the Bloviator and I had some discussions parsing out the 2002 uninsurance numbers. There was some controversy (that the two of us settled to our satisfaction, at least) about those numbers from the census bureau to do with how many of the 43 million it counted as uninsured were uninsured for the whole year. Now Health Affairs has published a Commonwealth Fund-sponsored article by Pamela Short and Deborah Grefe at Penn State that examines in great detail uninsurance between 1996 and 1999. While this data is of necessity a little old, you must remember that we were in an employment boom then–so things were as good as they were ever going to get for employment-based insurance in the modern economy–and also that things are worse now.  Still, onto the highlights.

The authors looked at large slice of the non-Medicare under-65 population which had approximately 225 million adults.  (It excluded immigrants, newborns and some others). Out of that 225 million number 84 million (37%) were uninsured at some time in the 4 years. Of those 84 million roughly 15 million (or 6% of the total) were more or less uninsured the whole time. As for the rest, the authors use a fairly complicated 6 way breakdown which I will grossly over-simplify into the fact that 50 million were uninsured for 5 months or more during that four year period. Roughly 32 million of that sub-group (64%) were uninsured for at least a year or more. If you are counting along at home that leaves another 20 million who had one or more short breaks in their coverage of less than 5 months.

So in my assessment, what’s new about this research? 

1) Well it’s usually assumed that at any one time 20 odd million are uninsured for a whole year (a little less than half the 43 odd million uninsured at any one time).  But if you take this rolling view rather than the snapshot, you have 15 million hard-core uninsured essentially for ever and another 32 million who’ve had a year or more uninsured in a four year period.  So rather than the 43 million oft-quoted snapshot number, some 57 million have been uninsured for more than a year in a four year period. These are the hard core uninsured and they measure nearly 25% of adults. And incidentally that is more people than voted for any one candidate in the 2000 election.

2) Counting this crudely, and making some assumptions, there seem to be three groups; one that is nowhere near getting insurance, One that is swinging between government programs like Medicaid, some employer based insurance and no insurance, and a smaller group that is cobbling together a patchwork of employer insurance, individually-bought insurance and uninsurance. The first two groups are the lower income ones.

The authors conclusions are that separate policy solutions are needed for each group–unless we have universal coverage.  That’s true in so far as it goes, but the authors know and (restrained by the terms of this data study) don’t state that the peverse dynamics of the individual insurance "market", the cost of COBRA coverage, and the difficulty of maintaining Medicaid coverage, all combine to make viable policy solutions targeted to sub-groups of the uninsured almost impossible to create.  The only actual options for universal insurance are :
a)some kind of employer-mandate, or
b)some kind of individual-mandate, both backed-up by government schemes either in terms of premium support for the poor or guaranteed insurance (e.g. Medicaid expansion). Or
c) of course single payer, Medicare for all.

There is clearly no political will for any of these reforms now. But perhaps if word gets out that not only is one in seven people uninsured now, but over one in three of us might be in this jam sometime in the next four years, that political will might become more apparent. One thing we do know: voluntary universal insurance is a fiction.

PBMs: No one’s listening to me?

0

Despite my doubts as to whether we’re going to get a Medicare drug bill, the market has decided a) that we will and b) that the PBMs are going to benefit the most from it. The last two days have seen a 10% rise in the PBMs stock price, and in the last 2 months they’ve gone up above their all time highs of 2 years ago. Somewhere a little north of here, I feel a pullback is imminent–perhaps I can just get word to Ted Kennedy and we can split a short position together?

TECHNOLOGY/INDUSTRY: More Tenet-related scuttlebutt

0

Not that it’s my natural proclivity, but I am enjoying the rumor-mongering abilities that writing this kind of a blog gives me. You’ll recall a while back that I came upon some rumors that Tenet had hired a company for its JCAHO reporting that may have put at risk its ability to remain certified to treat Medicare patients.

The latest I’ve heard is that this company is having problems with a related product. Apparently they found out that no (database) tables were being created for 7 types of medical errors that hospitals report using their software (e.g. medication errors, falls, etc.).  The error was part of a production release sent out over a month ago.  In other words, the 10 hospitals using the product could have (and probably did) reported adverse incidents using the system for over a month and the data for those incidents (that would be used to defend themselves in court, identify risky situations, prevent medication errors, etc.) would be lost. Apparently the head of QA recently left and another senior QA guy followed suit, resulting in a "go along to get along" QA department. 

This is a perfect example of how rushing software to market (without testing, let alone a detailed technical design document) can lead to big mistakes. Apparently this company develops on an ad-hoc basis, often sending out production releases every week.